Busan loses World Expo 2030 bid
Apgujeong Rolls Royce hit-and-run victim dies after 4 months in coma
N. Korea says spy satellite took photos of White House, Pentagon, key US naval base
Yoon apologizes for Busan's Expo bid failure; Mayor open to 2035 rebid
South Korea warns tit-for-tat action over North Korea’s border buildup
S. Korea's Busan making last-ditch efforts to bring World Expo on voting day
Korea, Japan, China summit likely in early 2024
YouTuber suspected of livestreaming after taking drugs
[Herald Interview] 'Korea strives to set global standards for data protection in generative AI era'
China’s AliExpress eyes expansion in Korea
Deargen-FarmHannong, a Co-Development Agreement to Develop AI-Powered Crop Protection ProductsBy
Published : Aug. 5, 2021 - 21:21
- Deargen's AI-Drug Discovery Platform, expanding to crop protection products
- FarmHannong, a subsidiary of LG Chem, accelerating the development of global crop protection products that utilizes artificial intelligence for the first time in Korea
SEOUL, South Korea, Aug. 5, 2021 /PRNewswire/ -- Deargen (CEO Kilsoo Kang), an artificial intelligence (AI)-Powered drug discovery and development company, announced on the 5th that it signed a co-development agreement with FarmHannong (CEO Youjin Lee) on the "development of new crop protection products using AI technology."
(outside the screen, from left) Deargen's CBO Youngchul Bae, CEO Kilsoo Kang, CTO Sungsoo Park, and CDO Inhwan Bae (in the screen, from left) FarmHannong's Hye-Jung Lee (Professional Researcher), CEO Youjin Lee, Kyung Myung (Innovative Technology Department Leader), and Junhyuk Choi (Crop Protection Team Leader)
Through this agreement, Deargen and FarmHannong will use artificial intelligence technology for the co-development of new drug candidate discovery for crop protection products. Through this contract, which aims to develop global crop protection products, Deargen is planning to receive upfront (contract deposit) as well as a milestone (technology fee per level) according to development progress from FarmHannong.
Deargen will be responsible for discovering and optimizing new chemical candidates of crop protection products through self-developed artificial intelligence technologies, DearDTI and MolEQ. Afterwards, FarmHannong will review the possibility of product development through experimental verification of new chemical candidates.
As the world population is growing, agricultural production is expected to increase by about 50% by 2050. Except for external environmental factors, such as natural disasters, the greatest impact on harvest can be the occurrence of disease and the effect of weeds. The size of the global crop protection products market is expected to be around 77 trillion won (approximately USD 67.3 billion), and the need to develop crop protection products of new technologies continues to increase as the resistance issue of existing crop protection products increases.
The principles for new drug development and the initial development of crop protection products are the same in that they discover new targets and discover new chemical candidates for targets. Based on this perspective, AI technologies from the existing drug development can be used to develop crop protection products, and collaboration between AI drug discovery companies and agricultural companies is taking place globally. Global pharmaceutical company Bayer has signed co-development contracts with AI drug discovery companies Kebotix and Atomwise for crop protection products development. In addition, the global crop protection products development company Syngenta launched two co-developments this year with Insilico Medicine and ENKO.
Based on this market trend, the agreement is noteworthy in that the AI technology utilized in the drug discovery is the first case in Korea to be applied to the crop protection products market.
Youjin Lee, CEO of FarmHannong, states, "In the agricultural sector, digital transformation (DX) innovation such as AI will be accelerated," and "we will innovate customer value by expanding technology development for agricultural customers with Deargen, which shows global AI technology through global academic conferences and research."
Kilsoo Kang, CEO of Deargen, said, "The development of crop protection products is limited in traditional ways, as is the case with new drug development. The data used in Deargen's artificial intelligence technology can cover not only human proteins but also animals, insects, viruses, and other species, which can be used for crop protection products development," and claimed "We are pleased to conduct co-development using AI technology from FarmHannong and Deargen, which have extensive experience in agriculture."
FarmHannong, a subsidiary of LG Chem(KRX: 051910) is first place in crop protection material market share and second in seed and fertilizer market share, and it is serving as a leader for improving the competitiveness and for the globalization of Korean agriculture based on extensive experience and advanced technologies. FarmHannong vows to be the true partner of farmers through best quality products and services and distinguished farming solutions to contribute in improving farming productivity and supplying safe foods. By concentrating on the development of next-generation products such as new crop protection materials, functional seeds, controlled release fertilizers, etc., we will help realize easy farming and sustainable farming. Under the vision of 'To be a Green Bio Company Enriching Human Life by providing differentiated customer value', FarmHannong will grow as a global green bio company that contributes to the construction of a healthy future. https://www.farmhannong.com/
About Deargen Inc.
Established in December 2016, Deargen (CEO: Kilsoo Kang) is an AI-based drug discovery and development company. In February 2020, the company released study results on predicting the development of COVID-19 treatments. Candidate compounds for treating COVID-19 predicted by Deargen include remdesivir, which was first approved as an emergency therapy. The company conducts research on and owns core AI technologies in-silico, such as 'prediction of bio-markers', 'selection of disease targets', and 'extraction of candidate substances for new drugs', utilizing techniques of meta analysis of genome big data and its unique AI technologies. Building on these outcomes, the company is developing new drugs in collaboration with multiple pharmaceutical companies and research institutions, demonstrating its outstanding technology capabilities as being named as top awardees at the ILSVRC, a world-prominent deep-learning competition, and Dream Challenge, an international AI-based new drug development competition.
Deargen Inc. Contact
Riaa Kim, firstname.lastname@example.org
Related Links :
Yoon apologizes for Busan's Expo bid failure; Mayor open to 2035 rebid
AI robots to aid English education in Seoul schools
Seoul reviews scenarios for restoring guard posts in DMZ